BioStock: Alzinova’s CEO - “we are a top actor in the Alzheimer’s field”

Alzinova has appointed board member Dr Carol Routledge as acting CEO. The move comes as the company continues its search for a permanent CEO after Kristina Torfgård announced her resignation from the post in the spring. BioStock contacted Routledge to learn more about her interim role as Alzinova prepares for phase II with its Alzheimer’s therapeutic vaccine ALZ-101.

Läs hela artikeln på biostock.se:

Alzinova’s CEO: “we are a top actor in the Alzheimer’s field” - BioStock

Detta är ett pressmeddelande från BioStock – Connecting Innovation & Capital. https://www.biostock.se